Summaries for Patients |

Rosuvastatin to Prevent Heart Problems and Stroke in Persons 70 Years or Older FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial.” It is in the 20 April 2010 issue of Annals of Internal Medicine (volume 152, pages 488-496). The authors are R.J. Glynn, W. Koenig, B.G. Nordestgaard, J. Shepherd, and P.M Ridker.

Ann Intern Med. 2010;152(8):I-34. doi:10.7326/0003-4819-152-8-201004200-00002
Text Size: A A A

What is the problem and what is known about it so far?

Low-density lipoprotein (LDL) cholesterol is the “bad” cholesterol that increases a person's risk for cardiovascular disease (heart problems or stroke). C-reactive protein is another substance in the blood that serves as a marker for cardiovascular disease risk. Statins are drugs that lower both LDL cholesterol and C-reactive protein levels. It has been known for a long time that statins reduce cardiovascular disease in persons with high levels of LDL cholesterol. In 2008, a study showed that the statin rosuvastatin reduced cardiovascular problems in persons with no previous cardiovascular disease and normal LDL cholesterol levels but elevated levels of C-reactive protein. The results of the initial report of this study suggested that rosuvastatin benefited persons regardless of their age. However, this study included larger numbers of older persons than did many previous studies of statins and provided an opportunity to look closely at the benefits and risks of this statin in older persons.

Why did the researchers do this particular study?

To compare the safety and efficacy of rosuvastatin in older versus younger persons.

Who was studied?

17,802 persons with LDL cholesterol levels less than 130 mg/dL and C-reactive protein levels of 2.0 mg/L or more who had no previous heart problems or stroke. Of these persons, 5695 were 70 years or older.

How was the study done?

The researchers compared the rates of heart problems and stroke observed in persons older than 70 years who did and did not take rosuvastatin.

What did the researchers find?

Among persons older than 70 years, fewer heart problems and strokes occurred in those who took rosuvastatin than in those who did not. As expected, because cardiovascular disease is more common as persons age, the absolute benefit of rosuvastatin was greater in older versus younger persons. However, rosuvastatin did not result in significant changes in the overall death rates over 2 years in persons older than 70 years.

What were the limitations of the study?

The study was ended early, which limited the information on the effects of treatment beyond 2 years. No persons in the study had normal C-reactive protein levels, so this study cannot report whether the measurement of this risk factor is necessary to identify persons who might have fewer cardiovascular problems if they take rosuvastatin.

What are the implications of the study?

Rosuvastatin seems to reduce heart problems and stroke but not overall death rates in persons older than 70 years who have never had cardiovascular problems and have normal LDL cholesterol levels but have high C-reactive protein levels.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.